Aggressiveness of advanced
melanomas relates in part to their marked propensity to develop neoangiogenesis and
metastases. Among its numerous pro-
cancer roles,
galectin (gal)-1 expressed and/or secreted by both
cancer and endothelial cells stimulates proliferation and angiogenesis. This study first shows that
gal-1 is more highly expressed at both
mRNA and
protein levels than its congeners in
melanomas and particularly in advanced lesions. The roles of
gal-1 were further investigated in vivo in the highly proliferating and vascularized pseudometastatic B16F10 mouse
melanoma model using stable knockdown B16F10 cells and wild-type versus
gal-1 knockout mice, and then in vitro in B16F10 tumoral and lung microvascular cells.
Gal-1 depletion in the B16F10
tumor cells but not in the
tumor-bearing mice significantly increased
melanoma-bearing mice survival.
Tumor-derived
gal-1 thus seems to have more critical roles than the host-derived one. In fact,
gal-1 displays distinct effects on the H-Ras-dependent p53/p21 pathways: in primary lung microvessel endothelial cells,
gal-1 seems to be involved in the maintenance of senescent status through the induction of both p53 and p21 while it stimulates B16F10
cancer cell proliferation through a p53/p21 decrease. Altogether, these data point to
gal-1 as a potential target to combat
melanomas.